The Nimble acquisition, which follows the $1.4 billion buy of Aliada Therapeutics in October, will help AbbVie rebuild and ...
AbbVie ABBV announced that it has entered into a definitive agreement to acquire privately held biotech, Nimble Therapeutics.
The acquisition includes Nimble's investigational candidate, an oral peptide IL23R inhibitor to treat psoriasis.
The pharma will pay $200 million to buy Nimble and a preclinical oral drug that blocks a protein known as IL-23 — the target ...
Buying Nimble Therapeutics represents AbbVie's latest deal to build out a pipeline in the wake of fading sales of its once ...
AbbVie has agreed to buy privately held biotechnology company Nimble Therapeutics for $200 million in cash in a deal that bolsters the biopharmaceutical company's expansive immunology portfolio.
Nimble sells the Fold 3-in-1 Wireless Charger exclusively through the Apple Store, both online and in person. It comes in ...
All 3-in-1 models are Qi2 Certified and MagSafe compatible. Delivering fast, efficient wireless charging for iPhone, Apple ...
Jack Nimble, the social-first creative agency and production company, has announced a significant leadership transition as it ...
AbbVie (ABBV) and Nimble Therapeutics announced a definitive agreement under which AbbVie will acquire Nimble, including its lead asset, an investigational oral peptide IL23R inhibitor in preclinical ...